Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a critical survival pathway frequently activated in various cancers.
• Constitutive activation stems from genetic alterations (PTEN loss, PI3K/Akt mutations) and external factors, driving cancer initiation and progression.
• This pathway's activation confers resistance to cancer therapies and is linked to poor patient prognosis.

Purpose of the Study:

• To review the clinical progress of targeted agents inhibiting the PI3K/Akt/mTOR pathway.
• To explore combination strategies involving these inhibitors with conventional and novel cancer treatments.
• To discuss challenges in clinical trial design, toxicity, and patient selection for PI3K/Akt/mTOR targeted therapies.

Main Methods:

• Review of clinical trial data for Akt inhibitors (perifosine, PX-866) and mTOR inhibitors (rapamycin, CCI-779, RAD-001).
• Analysis of preclinical and clinical studies on combination therapies.
• Discussion of regulatory and practical considerations for targeted pathway inhibition.

Main Results:

• Akt and mTOR inhibitors show promise in clinical trials, with ongoing research into their efficacy.
• Combination strategies aim to overcome resistance and enhance therapeutic outcomes.
• Complex pathway regulation presents challenges for optimal drug development and patient stratification.

Conclusions:

• Targeting the PI3K/Akt/mTOR pathway represents a promising strategy in oncology.
• Further research is needed to optimize combination therapies and address challenges in clinical application.
• Personalized approaches considering pathway activation and patient selection are crucial for successful treatment.